On this page
Sodium acetate anhydrous
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Sodium Acetate Anhydrous | 164 mg/mL | 801451 | View |
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 219826-001 | SODIUM ACETATE | SOLUTION | SODIUM ACETATE | Prescription | AP | ||
| 219826-002 | SODIUM ACETATE | SOLUTION | SODIUM ACETATE | Prescription | AP |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | September 18, 2025 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251021). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingPharmacy Bulk Package. Not for Direct Infusion
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Sodium acetate injection (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Sodium acetate injection (2 mEq/mL) is administered intravenously only after dilution in a larger volume of fluid . The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, transfer the desired amount to other intravenous fluids to provide the appropriate number of milliequivalents (mEq) of sodium acetate. Sodium acetate injection (2 mEq/mL) in the pharmacy bulk package is designed for use with manual, gravity flow operations and automated compounding devices for preparing intravenous nutritional admixtures. Admixtures must be stored under refrigeration and used within 24 hours after compounding. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (See PRECAUTIONS ). Directions for Dispensing From Pharmacy Bulk Package The pharmacy bulk package is for use in the pharmacy admixtures service only. For hanger application, peel off the paper liner from both ends of the tape hanger to expose 3⁄4 inch long adhesive portions. Adhere each end to the label on the bottle. The vials should be suspended as a unit in the laminar flow hood. A single entry through the vial closure should be made with a sterile dispensing set or transfer device. Transfer individual doses to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended as it may cause leakage and multiple entries will increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. Discard any unused portion within 4 hours after initial closure entry.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Sodium acetate injection (2 mEq/mL) is contraindicated in patients with hypernatremia or fluid retention.
Warnings
openFDA Drug LabelingWARNINGS Sodium acetate injection (2 mEq/mL) must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium free solutions may result in significant hypokalemia. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions (See WARNINGS and PRECAUTIONS ).
Description
openFDA Drug LabelingDESCRIPTION Sodium acetate injection, USP (2 mEq/mL) is a sterile, nonpyrogenic, concentrated solution of sodium acetate in water for injection. The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. Each mL contains 164 mg of sodium acetate (anhydrous) which provides 2 mEq each of sodium (Na+) and acetate (CH 3 COO-). The solution contains no bacteriostat, antimicrobial agent or added buffer. May contain glacial acetic acid for pH adjustment; the pH is 6.5 (6.0 to 7.0). The osmolar concentration is 4 mOsmol/mL (calc.); specific gravity 1.081. The solution is intended as an alternative to sodium chloride to provide sodium ion (Na+) for addition to large volume infusion fluids for intravenous use. Sodium acetate, USP anhydrous is chemically designated CH 3 COONa, a hygroscopic powder very soluble in water. A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.
Overdosage
openFDA Drug LabelingOVERDOSAGE In the event of overdosage, discontinue infusion containing sodium acetate immediately and institute corrective therapy as indicated to reduce elevated serum sodium levels, and restore acid-base balance if necessary (See WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Sodium acetate injection, USP (2 mEq/mL) is supplied in pharmacy bulk packages as follows: Unit of Sale Concentration Each NDC 70069-047-25 Case Containing 25 Units 100 mEq/50 mL (2 mEq/mL) NDC 70069-047-01 Glass Fliptop Vial NDC 70069-048-20 Case Containing 20 Units 200 mEq/100 mL (2 mEq/mL) NDC 70069-048-01 Glass Fliptop Vial Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: SODIUM ACETATE ANHYDROUS. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Shortages
Source: FDA Drug Shortages| Status | Availability | Company | Presentation | Updated |
|---|---|---|---|---|
| Current | Available | Somerset Therapeutics, LLC | Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25) | September 11, 2026 |
| Current | Available | Somerset Therapeutics, LLC | Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20) | September 11, 2026 |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 70069-047-25 | 70069-047 | Somerset Therapeutics, LLC | 25 VIAL, GLASS in 1 CARTON (70069-047-25) / 50 mL in 1 VIAL, GLASS | October 23, 2025 |
| 70069-048-20 | 70069-048 | Somerset Therapeutics, LLC | 20 VIAL, GLASS in 1 CARTON (70069-048-20) / 100 mL in 1 VIAL, GLASS | October 23, 2025 |
| 70069-047 | 70069-047 | Somerset Therapeutics, LLC | — | October 23, 2025 |
| 70069-048 | 70069-048 | Somerset Therapeutics, LLC | — | October 23, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Drug Shortages | FDA | Supply availability |
Generated September 25, 2026 · 11 sections on this page.